Gül Baktır


Therapeutic drug monitoring specializes in the measurement of drug concentrations in biological fluids and may serve as a practical aid to clarify various conditions of unexpect response to chronic drug treatment. Briefly, its main purpose is to optimize and/or individualize dosage regimens to maintain efficient and safe drug therapy.  This is acieved by maintaining serum/plasma drug concentrations within a target range (therapeutic range, therapeutic window),  which is defined as the range of plasma drug concentrations that produce therapeutic effects with minimal risk of adverse responses/side or toxic effects. In this review,  indications, practical applications as well as the clinical value and cost-effectiveness of therapeutic drug monitoring is discussed.


Therapeutic drug monitoring; therapeutic range; therapeutic window; clinical pharmacology; clinical pharmacy

Full Text:



Gadepalli R. Therapeutic Drug Monitoring [Lecture notes on internet].2015 [cited 2017 Dec]. Available from:

Buchthal F, Svensmark O, Schiller PJ. Clinical and electroencephalographic correlations with serum levels of diphenylhydanotin. Arch Neurol. 1960; 2:624–630.

Kutt H, Winters W, Kokenge R, McDowell F. Diphenylhydantoin metabolism, blood levels and toxicity. Arch. Neurol. 1964; 11: 642-648.

Lund, L. Anticonvulsant effect of diphenylhydantoin relative to plasma levels. Arch. Neurol.1974; 31: 289-294.

Duhme DW, Greenblatt DJ, Koch-Weser J. Reduction of digoxin toxicity associated with measurement of serum levels: a report from the Boston Collaborative Drug Surveillance program. Ann Intern Med. 1974; 80:516–519.

Atkinson AJ, Jr, Nordstorm K. The challenge of in-hospital medication use: an opportunity for clinical pharmacology. Clin Pharmacol Ther. 1996; 60:363–367.

Shenfield GM. Therapeutic drug monitoring beyond 2000. Br J Clin Pharmacol. 2001;52(Suppl 1):3S–4S.

Ensom MH, Davis GA, Cropp CD, Ensom RJ. Clinical pharmacokinetics in the 21st century: does the evidence support definitive outcomes?. Clin Pharmacokinet. 1998; 34:265-279.

Bochner F, Tonkin A. The clinician and therapeutic drug monitoring in the 1990s. Med J Aust. 1993;158:422-426.

Reynolds DJ, Aronson JK. ABC of monitoring drug therapy: making the most of plasma drug concentration measurements. BMJ. 1993;306:48-51.

Gross AS. Best practice in therapeutic drug monitoring. Br J Clin Pharmacol. 2001; 52 (Suppl 1): 5S-10S.

Aronson JK, Hardman M. ABC of monitoring drug therapy: measuring plasma drug concentrations. BMJ. 1992;305:1078-1080.

Burton ME, Shaw LM, Schentag JJ, Evans WE. Applied Pharmacokinetics & Pharmacodynamics. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2006. Principles of Therapeutic Drug Monitoring.

Ghiculescu, RA. Therapeutic drug monitoring: which drugs, why, when and how to do it. Aust Prescr. 2008;31(2):42-4.

Winter ME. Basic Clinical Pharmacokinetics. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2004:73-74.

Winter ME. Part 1: interpretation of plasma drug concentration. In: Winter ME, ed. Basic Clinical Pharmacokinetics. 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2004:73-96.

Glazko AJ. Phenytoin, chemistry and methods of determination. In: Levy RH, ed. Antiepileptic Drugs. 3rd ed. New York: Raven Press, 1989:159-176.

Steijns LS, Bouw J, van der Weide J. Evaluation of fluorescence polarization assays for measuring valproic acid, phenytoin, carbamazepine and phenobarbital in serum. Ther Drug Monit. 2002; 24:432-435.

Frank EL, Schwarz EL, Juenke J, Annesley TM, Roberts WL. Performance characteristics of four immunoassays for antiepileptic drugs on the IMMULITE 2000 automated analyzer. Am J Clin Pathol. 2002; 118:124-131.

Wu SL, Li W, Wells A, Dasgupta A. Digoxin-like and digitoxin-like immunoreactive substances in elderly people: impact on therapeutic drug monitoring of digoxin and digitoxin concentrations. Am J Clin Pathol 2001;115:600-604.

Steimer W, Muller C, Eber B. Digoxin assays: frequent, substantial and potentially dangerous interference by spironolactone, canrenone and other steroids. Clin Chem 2002;48:507-516.

Somerville AL, Wright DH, Rotschafer JC. Implication of vancomycin degradation products on therapeutic drug monitoring in patients with end-stage renal disease. Pharmacotherapy 1999;19:702-707.

Sym D, Smith C, Meenan G, Lehrer M. Fluorescence polarization immunoassay: can it result in an overestimation of vancomycin in patients not suffering from renal failure? Ther Drug Monit 2001;23:441-444.

Larkin JG, Herrick AL, McGuire GM, Percy-Robb IW, Brodie MJ. Antiepileptic drug monitoring at the epilepsy clinic: a prospective evaluation. Epilepsia 1991;32:89-95.

Vozeh S. Cost-effectiveness of therapeutic drug monitoring. Clin Pharmacokinet 1987;13:131-140.

Spector R, Park GD, Johnson GF, Vesell ES. Therapeutic drug monitoring. Clin Phamacol Ther 1988;43:345-353.

McInnes GT. The value of therapeutic drug monitoring to the practising physician: an hypothesis in need of testing. Br J Clin Pharmacol 1989;27:281-284.

Sjoqvist F. Interindividual differences in drug responses: an overview. In: Rowald M, Sheiner LB, Steiner JL, eds. Variability in Drug Therapy. New York: Raven Press, 1985:1-10.

McInnes GT. The value of therapeutic drug monitoring to the practising physician: an hypothesis in need of testing. Br J Clin Pharmacol 1989;27:281-284.

Rane CT, Dalvi SS, Goptay NJ, Shah PU, Kshirsagar NA. A pharmacoeconomic analysis of the impact of therapeutic drug monitoring in adult patients with generalized tonic-clonic epilepsy. Br J Clin Pharmacol 2001;52:193-195.

Ried LD, Horn JR, McKenna DA. Therapeutic drug monitoring reduces toxic drug reactions: a meta-analysis. Ther Drug Monit 1990;12:72-78.

Bootman JL, Harrison DL. Pharmacoeconomics and therapeutic drug monitoring. Pharm World Sci 1997;19:178-181.

Destache CJ, Meyer SK, Bittner MJ, Hermann KG. Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides: a cost-benefit analysis. Ther Drug Monit 1990; 12:419-426.

van Lent-Evers NA, Mathot RA, Geus WP, van Hout BA, Vinks AA. Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. Ther Drug Monit 1999;21:63-73.

Streetman DS, Nafziger AN, Destache CJ, Bertino AS Jr. Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs. Pharmacotherapy 2001;21:443-451.

Shaw LM, Kaplan B, Brayman KL. Prospective investigations of concentration-clinical response for immunosuppressive drugs provide the scientific basis for therapeutic drug monitoring. Clin Chem 1998;44:381-387.

Holt DW, Armstrong VW, Griesmacher A, Morris RG, Napoli KL, Shaw LM. International Federation of Clinical Chemistry /International Association of Therapeutic Drug Monitoring and Clinical Toxicology working group on immunosuppressive drug monitoring. Ther Drug Monit 2002;24:59-67.

Touw DJ, Neef C, Thomson AH, Vinks AA. Cost-effectiveness of therapeutic drug monitoring: a systemic review. Ther Drug Monit 2005;27:10-17.


  • There are currently no refbacks.